SCHEMBL2869401

SCHEMBL2869401

O=C(CC1NC(=O)NC1=O)NCCc1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.60
KDM4E B2RXH2 5/20 0.60
TAAR1 Q96RJ0 1/20 0.60
HSD17B10 Q99714 5/20 0.56
HPGD P15428 3/20 0.56
MAPT P10636 3/20 0.56
POLB P06746 1/20 0.56
MAPK1 P28482 1/20 0.56
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HTT P42858 1/20 0.50
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
CNR1 P21554 1/20 0.46
CASP1 P29466 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2872022 0.96 ALDH1A1 (0.57) ALDH1A1KDM4ETAAR1HSD17B10HPGD
SCHEMBL2874485 0.93 ALDH1A1 (0.58) ALDH1A1KDM4ETAAR1HSD17B10HPGD
SCHEMBL2871924 0.90 ALDH1A1 (0.53) ALDH1A1KDM4ETAAR1HSD17B10HPGD
SCHEMBL2875999 0.88 ALDH1A1 (0.59) ALDH1A1KDM4ETAAR1HSD17B10HPGD
SCHEMBL2872651 0.88 ALDH1A1 (0.59) ALDH1A1KDM4ETAAR1HSD17B10HPGD
SCHEMBL2865165 0.87 ALDH1A1 (0.53) ALDH1A1KDM4ETAAR1HSD17B10HPGD
SCHEMBL2869386 0.86 ALDH1A1 (0.67) ALDH1A1KDM4ETAAR1HSD17B10HPGD
SCHEMBL2870661 0.86 ALDH1A1 (0.67) ALDH1A1KDM4ETAAR1HSD17B10HPGD
SCHEMBL2865058 0.85 ALDH1A1 (0.56) ALDH1A1KDM4ETAAR1HSD17B10HPGD
SCHEMBL2874362 0.85 ALDH1A1 (0.56) ALDH1A1KDM4ETAAR1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354940-B2 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2008-04-08 US claimed
EP-1542977-B1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2006-12-20 EP claimed
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2005-11-03 US claimed
EP-1542977-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. AstraZeneca AB (SE) 2005-06-22 EP claimed
WO-2004020415-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2004-03-11 WO claimed
US-7662845-B2 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 ASTRAZENECA AB (SE) 2010-02-16 US disclosed
US-7354940-B2 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2008-04-08 US disclosed
EP-1542977-B1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2006-12-20 EP disclosed
US-20060276524-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 ASTRAZENECA AB, A SWEDEN CORPORATION 2006-12-07 US disclosed
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2005-11-03 US disclosed
EP-1542977-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. AstraZeneca AB (SE) 2005-06-22 EP disclosed
WO-2004020415-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276524-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 MMP12, MMP13, MMP9 ALDH1A1 540/4885KDM4E 495/4885TAAR1 3719/4885
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 MMP12, PDE12, MMP13 ALDH1A1 441/4885KDM4E 553/4885TAAR1 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.